Data Supplement from The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer
التفاصيل البيبلوغرافية
العنوان:
Data Supplement from The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer
American Association for Cancer Research (AACR), 2023.
سنة النشر:
2023
الوصف:
Supplementary Table S1: Spearman correlations (rho) between biomarkers; Supplementary Table S2: Pre-chemotherapy/bevacizumab concentrations of individual angiogenesis associated factors; Supplementary Table S3: comparisons between biomarker parameters by treatment Arm; Supplementary Table S4: comparisons between biomarker parameters by time since surgery; Supplementary Table S5: Validation of the identified biomarkers in the training dataset using bootstrap resampling technique; Supplementary Table S6: Tumour response by Ang1/Tie2 combination categories by treatment in the training set; Supplementary Table S7: Cox proportional hazard models confirming Ang1 and Tie2 as a joint biomarker in the validation dataset (N = 114)
